Cargando…

Biomarkers can predict potential clinical responders to DIMS0150 a toll-like receptor 9 agonist in ulcerative colitis patients

BACKGROUND: Glucocorticoids (GCS) remain one of the mainstay treatments in the management of ulcerative colitis (UC) but up to a third of patients will ultimately fail to respond and progress to a more severe and difficult to manage disease state. Previous clinical studies suggest that the Toll-Like...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kuznetsov, Nikolai V, Zargari, Arezou, Gielen, Alexander W, von Stein, Oliver D, Musch, Eugen, Befrits, Ragnar, Lofberg, Robert, von Stein, Petra
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4005617/ https://www.ncbi.nlm.nih.gov/pubmed/24758565 http://dx.doi.org/10.1186/1471-230X-14-79

Ejemplares similares

Clinical Effects of a Topically Applied Toll-like Receptor 9 Agonist in Active Moderate-to-Severe Ulcerative Colitis
por: Atreya, Raja, et al.
Publicado: (2016)

TM0,1.5,0 mode cavity for longitudinal bunch feedback kicker
por: Shintake, T
Publicado: (1996)

EHMTI-0150. A controlled study of sleep in cluster headache patients.apo04
por: Barloese, M, et al.
Publicado: (2014)

P01.50. Influence of dietary red palm oil on antioxidant status in male Wistar rats
por: Ayeleso, A, et al.
Publicado: (2012)

PA01.50. Enriching Public Health Through: Nidana Parivarjana and Pathya Apthya w.e.r. to Amavata
por: Mishra, Nimisha, et al.
Publicado: (2012)

The TLR9 Agonist Cobitolimod Induces IL10-Producing Wound Healing Macrophages and Regulatory T Cells in Ulcerative Colitis
por: Schmitt, Heike, et al.
Publicado: (2020)

Use of complementary and alternative medicine in Swedish patients with inflammatory bowel disease: a controlled study
por: Oxelmark, Lena, et al.
Publicado: (2016)

Increased early activation of CD56(dim)CD16(dim/-) natural killer cells in immunological non-responders correlates with CD4(+) T-cell recovery
por: Zhang, Qiu-Yue, et al.
Publicado: (2020)

Exploring Anorectal Manometry as a Method to Study the Effect of Locally Administered Ropivacaine in Patients with Ulcerative Colitis
por: Arlander, Eva, et al.
Publicado: (2013)

EnanDIM - a novel family of L-nucleotide-protected TLR9 agonists for cancer immunotherapy
por: Kapp, Kerstin, et al.
Publicado: (2019)

CD56(dim)CD16(dim) Natural Killer (NK) Cells: The Forgotten Population
por: Zimmer, Jacques
Publicado: (2020)

Expression of Toll-like receptors in the mucosa of patients with ulcerative colitis
por: FAN, YUJING, et al.
Publicado: (2015)

Human CD56(dim)CD16(dim) Cells As an Individualized Natural Killer Cell Subset
por: Amand, Mathieu, et al.
Publicado: (2017)

Gender and the treatment of immune-mediated chronic inflammatory diseases: rheumatoid arthritis, inflammatory bowel disease and psoriasis: an observational study
por: Lesuis, Nienke, et al.
Publicado: (2012)

Safety and tolerability of DIM-based therapy designed as personalized approach to reverse prostatic intraepithelial neoplasia (PIN)
por: Paltsev, Mikhail, et al.
Publicado: (2014)

Dimming Titan Revealed by the Cassini Observations
por: Li, Liming
Publicado: (2015)

Dim Light Exposure and Myopia in Children
por: Landis, Erica G., et al.
Publicado: (2018)

The Plant Derived 3-3′-Diindolylmethane (DIM) Behaves as CB(2) Receptor Agonist in Prostate Cancer Cellular Models
por: Tucci, Paolo, et al.
Publicado: (2023)

Toll-Like Receptor 9 Agonists in Cancer
por: Karapetyan, Lilit, et al.
Publicado: (2020)

The impact of obesity on hospitalized patients with ulcerative colitis
por: El-Dallal, Mohammed, et al.
Publicado: (2021)

Dimness of Vision in Diseases of the Kidney Characterised by Albuminuria
por: Ramsay, A. Maitland
Publicado: (1902)

Brightening and Dimming Aftereffects at Low and High Luminance
por: Hassan, Omar, et al.
Publicado: (2018)

Rationale: Photosynthesis of Vascular Plants in Dim Light
por: Wang, Xiaolin, et al.
Publicado: (2020)

Toll-Like Receptor 9 Agonists for Cancer Therapy
por: Melisi, Davide, et al.
Publicado: (2014)

Toll-Like Receptor Agonists as Adjuvants for Allergen Immunotherapy
por: Kirtland, Max E., et al.
Publicado: (2020)

Applications and clinical trial landscape using Toll-like receptor agonists to reduce the toll of cancer
por: Rolfo, Christian, et al.
Publicado: (2023)

A comparison of myopia control in European children and adolescents with defocus incorporated multiple segments (DIMS) spectacles, atropine, and combined DIMS/atropine
por: Nucci, Paolo, et al.
Publicado: (2023)

Prediction and Verification of Potential Therapeutic Targets for Non-Responders to Infliximab in Ulcerative Colitis
por: Lyu, Xue, et al.
Publicado: (2023)

More than random responding: Empirical evidence for the validity of the (Extended) Crosswise Model
por: Meisters, Julia, et al.
Publicado: (2022)

Toll-Like Receptor 7 Agonist–Induced Dermatitis Causes Severe Dextran Sulfate Sodium Colitis by Altering the Gut Microbiome and Immune Cells
por: Kiyohara, Hiroki, et al.
Publicado: (2018)

Effect of toll-like receptor 3 agonist poly I:C on intestinal mucosa and epithelial barrier function in mouse models of acute colitis
por: Zhao, Hong-Wei, et al.
Publicado: (2017)

Protective Role of the Toll-Like Receptor 5 Agonist KMRC011 against Murine Colitis Induced by Citrobacter rodentium and Dextran Sulfate Sodium
por: Kim, Jun-Young, et al.
Publicado: (2023)

The role of quantized 2-dim. gravity in string theory
por: Dhar, A, et al.
Publicado: (1990)

Neural Mechanism for Sensing Fast Motion in Dim Light
por: Li, Ran, et al.
Publicado: (2013)

Bumblebees Perform Well-Controlled Landings in Dim Light
por: Reber, Therese, et al.
Publicado: (2016)

Preparation and Characterization of Whey Protein Isolate–DIM Nanoparticles
por: Khan, Abbas, et al.
Publicado: (2019)

Spectroscopic evidence for a large spot on the dimming Betelgeuse
por: Alexeeva, Sofya, et al.
Publicado: (2021)

New Results on Small and Dim Infrared Target Detection
por: Wang, Hao, et al.
Publicado: (2021)

From IBS to DBS: The Dysbiotic Bowel Syndrome
por: Benno, Peter, et al.
Publicado: (2016)

The Toll-Like Receptor Agonist Imiquimod Is Active against Prions
por: Oumata, Nassima, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_ldl12fpft35lui5m8g0bvpkpg8